Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvingtrans Regulatory News (AVG)

Share Price Information for Avingtrans (AVG)

Share Price is delayed by 15 minutes
Get Live Data
652.00    12.00 (1.88%)
Bid:
644.00
Ask:
660.00
Spread: 16.00 (2.484%)
Market Cap: £219.22m
AVG Live PriceLast checked at - London Stock Exchange

Intraday Avingtrans Share Chart

Exercise of Share Options

13 Dec 2016 16:00

RNS Number : 7534R
Avingtrans PLC
13 December 2016
 

Avingtrans Plc

("Avingtrans" or the "Company" or the "Group")

 

Exercise of Share Options

 

Avingtrans (AIM:AVG), a manufacturer of critical components and associated services to the global aerospace, energy and medical sectors announces that on 13 December 2016 the Company issued 14,001 ordinary shares of 5 pence each ("Ordinary Shares") following the exercise of options under the Company's CSOP share option scheme.

 

Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 19 December 2016 ("Admission"). Upon Admission, the new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

 

After Admission, the Company's total issued share capital is 18,348,889 Ordinary Shares. Avingtrans does not hold any Ordinary Shares in treasury and therefore following Admission, the total number of voting rights in Avingtrans will be 18,348,889.

 

The above figure 18,348,889 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Avingtrans under the FSA's Disclosure Guidance and Transparency Rules. 

 

Enquiries:

Avingtrans plc

Steve McQuillan, CEO

Stephen King, CFO 

 

0135 469 2391

N+1 Singer

Shaun Dobson

Lauren Kettle

 

020 7496 3000

Newgate

(Financial PR)

Adam Lloyd

Ed Treadwell

020 7653 9850

 

About Avingtrans

 

Avingtrans plc is engaged in the provision of highly engineered components, systems and services to the energy, medical and traffic management industries worldwide.

 

Energy and medical, engaged in the design and manufacture of safety critical equipment for the energy, medical, science and research communities, including oil and gas extraction and processing equipment, nuclear process plant, machined and fabricated pressure and vacuum vessels and components. Also, design and manufacture of fabricated poles and cabinets for roadside safety cameras and rail track signalling.

 

The strategy of the group, is to "buy and build" in regulated engineering niche markets, where we can see potential consolidation opportunities, which can lead to significantly increased shareholder value over the medium to long term.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEASADFSEKFFF
Date   Source Headline
19th May 202610:20 amRNSHolding(s) in Company
14th May 202612:26 pmRNSHolding(s) in Company
12th May 20267:00 amRNSAdaptix receives CE Certification
6th May 20264:28 pmRNSHolding(s) in Company
30th Apr 20262:42 pmRNSHolding(s) in Company
30th Apr 20262:41 pmRNSExercise of Options & TVR
24th Apr 20262:54 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSStrong Nuclear Orders for Avingtrans
26th Mar 20267:00 amRNS-RScientific Magnetics Ships 20th Quantum Magnet
4th Mar 20267:00 amRNSHolding(s) in Company
25th Feb 20267:00 amRNSInterim Results
12th Feb 202611:49 amRNSHolding(s) in Company
6th Feb 202610:24 amRNSHolding(s) in Company
27th Jan 20265:42 pmRNSExercise of Options & TVR
21st Jan 20267:00 amRNSTrading Update and Notice of Results
12th Jan 20265:13 pmRNSIssue of Share Options
12th Jan 20267:00 amRNS-RMedical & Industrial Imaging Division Appointment
8th Dec 20252:34 pmRNSNotification of Major Holdings
27th Nov 20251:59 pmRNSResult of AGM - Board Appointment
14th Nov 20258:38 amRNSExercise of Options & PDMR Dealings
10th Nov 20257:00 amRNSAdaptix receives FDA 510(K) clearance
1st Oct 20254:52 pmRNSExercise of Options & Total Voting Rights
1st Oct 20253:32 pmRNSHolding(s) in Company
29th Sep 20257:00 amRNSAppointment of Medical Division CEO
24th Sep 20257:00 amRNSPreliminary results for the year ended 31 May 2025
11th Sep 20258:00 amRNSHolding(s) in Company
2nd Sep 20257:00 amRNSHayward Tyler Secures $16m Nuclear Contracts
28th Aug 20257:00 amRNSBooth Industries secures £8.5m HS2 & TfL contracts
25th Jun 20257:00 amRNSTrading Update and Notice of Results
28th May 20257:00 amRNSTrading Update
26th Feb 20257:00 amRNSInterim Results
13th Feb 20257:00 amRNSBooth Industries secures £4.5m Contract
16th Jan 20257:00 amRNSTrading Update & Notice of Results
21st Nov 20244:09 pmRNSResult of AGM
24th Oct 20249:07 amRNSHolding(s) in Company
25th Sep 20247:00 amRNSPreliminary results for the year ended 31 May 2024
3rd Jul 20247:00 amRNSPDMR Dealings
19th Jun 20247:00 amRNSTrading Update and Notice of Results
26th Mar 202411:15 amRNSPDMR Dealings
21st Mar 20245:15 pmRNSExercise of Options, PDMR Dealings & TVR
20th Mar 20243:39 pmRNSHolding(s) in Company
4th Mar 20246:10 pmRNSPDMR Dealings
28th Feb 20247:00 amRNSInterim Results
18th Jan 20247:00 amRNSTrading Update and Notice of Results
15th Dec 20233:00 pmRNSExercise of Options & TVR
4th Dec 20237:00 amRNSMagnetica Limited appoints US distributor
22nd Nov 20237:00 amRNSEmployee & PDMR Share Incentive Awards
16th Nov 20232:20 pmRNSResult of AGM
13th Nov 20237:00 amRNSHayward Tyler Contract Win
11th Oct 20237:00 amRNSContract Wins

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.